The MOOD Research Study – Sponsored by Neurolief

General Page Media
MOOD study advertisement with depressed patient wearing device

Many people worldwide do not get sufficient benefit from antidepressant medications and are seeking alternative treatment options. The MOOD research study evaluates a new treatment with a self-administered investigational medical device for alleviating Major Depressive Disorder (MDD) symptoms. The study device is non-invasive and is used by participants at home at convenient times. Compensation for time and travel is available for eligible participants.

The study is sponsored by Neurolief Ltd and the purpose of this research is to evaluate whether the investigational Relivion®DP device is safe and helpful in alleviating Major Depressive Disorder (MDD) symptoms. Here’s a picture of the investigational non-invasive, external neuromodulation device: Relivion®DP. When activated, the device delivers mild electrical stimulation pulses which can be managed by the user and are intended to alleviate major depressive disorder symptoms.

Patient wearing Relivion DP device on forehead

Disclaimer: The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images and information, contained on or available through this website, is for general information purposes only. Please contact your physician to form a plan that addresses your specific needs.

To participate in the MOOD study, you must:

  • Be 18-70 years old.
  • Be diagnosed with MDD; current major depressive episode lasting up to 3 years.
  • Had inadequate response to at least one antidepressant medication or had to stop at least two antidepressant medications due to side effects.
  • Be currently taking an antidepressant medication.

To learn more about the MOOD study, please contact the Interventional Psychiatry Lab study team, overseen by Dr. Ziad Nahas, Department of Psychiatry and Behavioral Studies, University of Minnesota. 952-525-4505 OR [email protected]